CytomX Therapeutics, Inc. (CTMX) Profit Margins
Over the twelve months to 2026-06-30, CytomX Therapeutics, Inc. (CTMX) had operating margin -476.2%, net margin -435.2%, free cash flow margin -450.7%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CTMXCytomX Therapeutics, Inc.Follow CTMX — free
—
Price chart with a free account
- Market cap
- 505.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
| Line | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating margin | -430.5% | -396.1% | -64.6% | -130.9% | -525.9% | -117.7% | -311.0% | -190.6% | -6.4% | 18.1% | -29.3% | -476.2% | |
| Net margin | -458.7% | -391.5% | -60.2% | -142.2% | -493.7% | -94.7% | -310.5% | -186.8% | -0.6% | 23.1% | -22.8% | -435.2% | |
| FCF margin | -376.2% | -28.0% | 235.7% | -133.3% | -535.2% | 4.3% | -323.3% | -211.7% | -56.2% | -62.7% | -99.5% | -450.7% |
USD millions · SEC XBRL
CytomX Therapeutics, Inc. — questions
- What is CytomX Therapeutics, Inc.'s operating margin?
- -476.2% over the twelve months to 2026-06-30.
- What is CytomX Therapeutics, Inc.'s net profit margin?
- -435.2% over the twelve months to 2026-06-30.
Every figure on this page comes from CytomX Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.